Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Neurodegenerative Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1786389

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1786389

Dementia Treatment

PUBLISHED:
PAGES: 204 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Dementia Treatment Market to Reach US$30.1 Billion by 2030

The global market for Dementia Treatment estimated at US$19.5 Billion in the year 2024, is expected to reach US$30.1 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Alzheimer's Disease Dementia Indication, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$17.1 Billion by the end of the analysis period. Growth in the Vascular Dementia Indication segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 7.3% CAGR

The Dementia Treatment market in the U.S. is estimated at US$5.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global Dementia Treatment Market - Key Trends & Drivers Summarized

How Is the Rising Dementia Burden Shaping the Treatment Landscape?

Dementia has emerged as a significant global health challenge, with an aging population driving a surge in cases. According to the World Health Organization (WHO), over 55 million people worldwide are living with dementia, a number expected to nearly triple by 2050. The increasing prevalence of Alzheimer's disease, which accounts for 60-70% of dementia cases, has intensified the demand for effective treatments. The lack of curative therapies has made early diagnosis, symptomatic management, and disease-modifying interventions the key focus areas. Healthcare systems worldwide are struggling with the socio-economic burden of dementia, prompting governments and pharmaceutical companies to accelerate research and development (R&D) efforts. Drug development for dementia is particularly challenging due to the complexity of neurodegeneration, but recent breakthroughs in monoclonal antibody therapies, amyloid-beta inhibitors, and tau protein-targeting drugs offer hope for slowing disease progression. Additionally, non-pharmacological interventions such as cognitive therapies, brain stimulation, and lifestyle modifications are gaining attention as complementary treatment options. The emphasis on early detection through advanced imaging, blood biomarkers, and AI-driven diagnostics is transforming dementia treatment, enabling timely intervention before irreversible cognitive decline occurs.

Which Emerging Therapies Are Transforming Dementia Treatment?

The dementia treatment landscape is witnessing a shift from symptomatic management to disease-modifying therapies, with a wave of innovative drugs entering clinical trials. The recent approvals of amyloid-targeting drugs such as Aducanumab and Lecanemab have opened new possibilities, despite debates over their efficacy and cost-effectiveness. Monoclonal antibodies designed to clear amyloid plaques from the brain are being explored as potential disease-modifying treatments. Tau protein inhibitors, aimed at preventing neurofibrillary tangle formation, are also gaining momentum in late-stage trials. Additionally, cholinesterase inhibitors and NMDA receptor antagonists remain essential for managing cognitive symptoms. Beyond pharmacological solutions, novel therapies such as transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and gene therapy are showing promise in slowing disease progression. The growing interest in precision medicine and biomarker-driven treatment approaches is further transforming the dementia therapy landscape. Companies are investing heavily in RNA-based drugs, stem cell therapy, and neuroprotective agents that could offer long-term benefits. Meanwhile, the rise of digital therapeutics, including AI-powered cognitive training programs and wearable biosensors, is enabling continuous monitoring and intervention, enhancing patient outcomes.

How Are Regulatory and Market Dynamics Influencing Dementia Drug Development?

Regulatory agencies play a crucial role in shaping the dementia treatment market, balancing the urgent need for innovative therapies with safety and efficacy concerns. The accelerated approval of amyloid-targeting drugs by the U.S. Food and Drug Administration (FDA) has sparked discussions about fast-tracking dementia drug approvals. However, pricing and reimbursement challenges remain significant hurdles, with high-cost therapies limiting accessibility. The European Medicines Agency (EMA) and other global regulators are emphasizing rigorous clinical trials, demanding conclusive evidence of cognitive improvement before widespread approvals. Meanwhile, the rise of public-private partnerships is fostering greater collaboration between academia, biotech firms, and pharmaceutical giants, accelerating research breakthroughs. The increasing focus on personalized medicine is also influencing regulatory frameworks, as targeted therapies based on genetic and biomarker profiling gain traction. Additionally, governments and non-profit organizations are funding dementia research at unprecedented levels, recognizing its growing healthcare burden. While the high failure rate of dementia drug trials remains a challenge, advancements in AI-driven drug discovery and innovative clinical trial designs are improving success rates, reshaping the treatment pipeline.

What Factors Are Driving Growth in the Dementia Treatment Market?

The growth in the dementia treatment market is driven by several factors, primarily the rising global prevalence of dementia due to increasing life expectancy. The demand for early diagnosis and intervention has surged, leading to a growing focus on biomarker-based diagnostics and AI-powered screening tools. The introduction of disease-modifying drugs, particularly amyloid and tau-targeting therapies, has opened new revenue streams for pharmaceutical companies. Additionally, the expansion of home-based care and telemedicine solutions has increased access to dementia treatments, catering to patients in remote areas. Advances in neuroimaging and blood-based biomarkers are enhancing early detection, allowing patients to benefit from treatments before irreversible damage occurs. The increasing adoption of digital therapeutics, cognitive training apps, and smart monitoring devices is further complementing traditional treatment approaches. Furthermore, government initiatives, rising healthcare spending, and increased funding for neurodegenerative research are fostering a more robust dementia treatment ecosystem. The emergence of precision medicine, leveraging genetic and biomarker-based therapies, is expected to revolutionize dementia treatment in the coming years, positioning the market for rapid expansion.

SCOPE OF STUDY:

The report analyzes the Dementia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication, Frontotemporal Dementia (FTD) Indication, Parkinson Disease Dementia Indication, Other Indications); Drug Class (Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class, Other Drug Classes); Route of Administration (Oral Route of Administration, Transdermal Patch Route of Administration, Injectable Route of Administration); Distribution Channel (Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels, Online Pharmacy Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Aurobindo Pharma Ltd.
  • Biogen Inc.
  • Cipla Inc.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP30409

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Dementia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Aging Population Trends Throw the Spotlight on Dementia as a Growing Public Health Challenge
    • Rising Prevalence of Alzheimer's and Other Neurodegenerative Disorders Spurs Innovation in Disease-Modifying Therapies
    • Approval of Novel Monoclonal Antibody Treatments Strengthens the Business Case for Early-Stage Intervention
    • Increased Investment in Cognitive Health Fuels Pipeline Development in Small Molecule and Biologic Therapies
    • Shift Toward Personalized Medicine Supports Use of Biomarkers and Genetic Screening in Dementia Diagnosis
    • Expansion of Digital Therapeutics and Cognitive Training Platforms Enhances Non-Pharmacological Treatment Options
    • Growing Use of AI in Early Detection and Imaging Analysis Accelerates Diagnosis and Monitoring
    • Caregiver Burnout and Healthcare Burden Create Opportunities for In-Home and Community-Based Treatment Solutions
    • Improved Access to Memory Clinics and Cognitive Screening Tools Drives Diagnosis Rates Globally
    • Rising Participation in Clinical Trials and Real-World Evidence Studies Supports Regulatory Momentum
    • Pharma and Tech Partnerships Expand Cross-Disciplinary Approaches to Dementia Care
    • Health Policy Initiatives and National Dementia Plans Support Funding for Innovative Care Models
    • Increased Focus on Lifestyle Interventions and Nutrition Opens Holistic Treatment Opportunities
    • Integration of Telehealth in Neurology and Geriatrics Supports Remote Monitoring and Medication Adherence
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Dementia Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Dementia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Dementia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Alzheimer's Disease Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Alzheimer's Disease Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Vascular Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Vascular Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lewy Body Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Lewy Body Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Oral Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Transdermal Patch Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Transdermal Patch Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Injectable Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Injectable Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Hospital Pharmacy Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Hospital Pharmacy Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacy Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Retail Pharmacy Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Online Pharmacy Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Online Pharmacy Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitor Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Cholinesterase Inhibitor Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for NMDA Receptor Antagonist Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for NMDA Receptor Antagonist Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for MAO Inhibitor Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for MAO Inhibitor Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Combination Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Combination Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 34: USA Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • CANADA
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • JAPAN
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • CHINA
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 58: China Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 64: China Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: China 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • EUROPE
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Dementia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • FRANCE
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 76: France Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 82: France Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: France 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • GERMANY
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Germany 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • UNITED KINGDOM
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 100: UK Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 106: UK Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: UK 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of World 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!